# Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma

> **NCT03243851** · PHASE2 · COMPLETED · sponsor: **Yong-Kil Hong** · enrollment: 81 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Temozolomide+Metformin
- **DRUG:** Temozolomide+Placebo

## Key facts

- **NCT ID:** NCT03243851
- **Lead sponsor:** Yong-Kil Hong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-21
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2021-09-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03243851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03243851, "Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03243851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*